Page 20 - JCTR-9-5

Journal of Clinical and Translational Research 2023; 9(5): 322-326

Journal of Clinical and Translational Research

Journal homepage: http://www.jctres.com/en/home

ORIGINAL ARTICLE

Appropriate patient selection and overall survival after transarterial

radioembolization in colorectal adenocarcinoma liver metastases

Sharmeen Mahmood , Garo Hagopian , Ben Sadeghi , Jeffrey V. Kuo , David K. Imagawa , Dayantha Fernando ,
2
1
3
1
2
3
Nadine Abi-Jaoudeh , Farshid Dayyani *
1 †
2†
1 Department of Medicine, Division of Hematology/Oncology, University of California Irvine, Orange, California, United States of America,
2 Department of Radiological Sciences, Division of Vascular and Interventional Radiology, University of California Irvine, Orange, California, United
States of America, Department of Radiation Oncology Orange, University of California Irvine, California, United States of America, Department of
4
3
Surgery, Division of Hepatobiliary Surgery, University of California Irvine, Orange, California, United States of America
† These authors contributed equally to this work.
ARTICLE INFO ABSTRACT
Article history: Background and Aim: The objective of this study was to describe the overall survival (OS) with
Received: May 13, 2023 transarterial radioembolization (TARE) for patients with colorectal adenocarcinoma liver metastases
Revised: July 12, 2023 (CRLM) treated at an academic center with a dedicated multidisciplinary liver tumor board (MTB).
Accepted: July 12, 2023 Methods: Single institution retrospective study of consecutive patients with CRLM undergoing
Published Online: September 23, 2023 TARE with mainly Y90 resin spheres between 01/2016-07/2020.
Results: Fifty-five patients were included in the study. Median age was 60 years (range 36–84), 61.8%
Keywords: were female, Eastern Cooperative Oncology Group 0–1 = 90.9%. The median time from diagnosis
Colorectal liver metastases to first TARE was 16.4 months (1.7–95.6) and 36.4% were treated within the first 12 months of
Yttrium-90 spheres diagnosis. With a median follow-up of at least 2 years, the median OS from the date of diagnosis and
Transarterial radioembolization first TARE was 43.2 months (29.5–68.7) and 16.7 months (9.9–35.2), respectively.
Survival Conclusions: The observed OS in this cohort compares favorably to OS reported in contemporary
Phase 3 trials and might indicate a benefit of TARE with appropriate patient selection at experienced
*Corresponding author: centers with dedicated MTB.
Farshid Dayyani Relevance for Patients: Oncologists treating patients with CRLM should consider referral to a
University of California Irvine, Department of tertiary treatment center with a multidisciplinary team and TARE treatment expertise.
Medicine/Division of Hematology/Oncology,
200 S Manchester Ave, Orange, California
(CA) 92868, United States of America.
Tel: +1 714 456 8161 1. Introduction
Fax: +1 714 456 2242
Email: fdayyani@hs.uci.edu The liver is the most common site of distant metastasis in colorectal carcinoma (CRC)
with 50–70% of patients developing colorectal liver metastases (CRLM) during the
© 2023 Author(s). This is an Open-Access disease [1]. Liver failure is the main cause of death in CRC patients. Standard of care
article distributed under the terms of the treatment for CRLM includes curative intent resection and systemic therapy [1]. However,
Creative Commons Attribution-Noncommercial surgery is only applicable in 10–20% of cases, and of patients who undergo resection, long-
License, permitting all non-commercial use,
distribution, and reproduction in any medium, term remission is only achieved in 20% of cases [1]. Over the past two decades, there have
provided the original work is properly cited. been some advances in systemic therapy; however, control of liver metastases remains an
unmet need. Transarterial radioembolization (TARE) using yttrium-90 spheres (Y90) has
been shown to induce tumor responses and delay progression of CRLM across all lines of
treatment [2]. However, randomized trials in first and second-line CRLM patients failed to
show an overall survival (OS) benefit in unselected populations [3,4]. There is also a concern
that early exposure to internal liver radiation might lead to early and/or delayed radiation-
induced damage which could compromise long-term outcomes of patients [5]. The objective
DOI: http://dx.doi.org/10.18053/jctres.09.202305.23-00066